Jinglin Xia

11PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cardiology (incl. cardiovascular diseases)Medical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 22, 2026
GPX8+ cancer-associated fibroblast-derived lactate contributes to lenvatinib resistance by facilitating BRPF1 expression through histone H3 lysine 18 lactylation in hepatocellular carcinoma.

|Oct 01, 2025
Targeting JMJD6/PPARĪ³/GPX4 axis overcomes ferroptosis resistance and enhances therapeutic efficacy in hepatocellular carcinoma.

Jie Li, Shengwei Mao, Shiguang Yang

|Jul 23, 2025
Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial.

Jie Li, Bei Lv, Li Song

|May 23, 2025
PIP5K1A Suppresses Ferroptosis and Induces Sorafenib Resistance by Stabilizing NRF2 in Hepatocellular Carcinoma.

Mengzhou Guo, Sinuo Chen, Jialei Sun

|Sep 11, 2024
Diagnostic value of serum inflammatory markers in predicting early refractoriness of transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer Stage 0, A, and B hepatocellular carcinoma.

Junhui Yang, Yunjie Zhang, Yifan Kong

|Jul 17, 2024
Author Correction: Synergistic immunochemotherapy targeted SAMD4B-APOA2-PD-L1 axis potentiates antitumor immunity in hepatocellular carcinoma.

Feng Qi, Jian Zhang, Jia Li

Pageof 2

Frequent Collaborators

2 joint publications

Feng Qi

2 joint publications

Wenguo Cui

2 joint publications

Zhijie Yu

1 joint publications

Tuo Deng